Comparative Pharmacology
Head-to-head clinical analysis: OSELTAMIVIR PHOSPHATE versus TAMIFLU.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OSELTAMIVIR PHOSPHATE versus TAMIFLU.
OSELTAMIVIR PHOSPHATE vs TAMIFLU
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oseltamivir phosphate is a neuraminidase inhibitor. It is a prodrug that is hydrolyzed to the active metabolite oseltamivir carboxylate, which inhibits influenza A and B neuraminidases, preventing viral replication by blocking the cleavage of sialic acid residues and release of progeny virions.
Oseltamivir phosphate is a prodrug that is hydrolyzed to the active metabolite oseltamivir carboxylate, a selective inhibitor of influenza virus neuraminidase, an enzyme required for viral replication and release from infected cells.
75 mg orally twice daily for 5 days.
75 mg orally twice daily for 5 days
None Documented
None Documented
Oseltamivir carboxylate: 6-10 hours (terminal) in adults with normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <10 mL/min).
Terminal elimination half-life of oseltamivir carboxylate is 4.4 hours (range 3.9–5.0 h) in healthy adults, allowing twice-daily dosing; prolonged to 18–24 hours in severe renal impairment (CrCl <10 mL/min).
Renal: 60-70% of total clearance as oseltamivir carboxylate via glomerular filtration and tubular secretion; unchanged oseltamivir <5%. Fecal: <20% as oseltamivir carboxylate. Biliary: negligible.
Renal excretion of the active metabolite oseltamivir carboxylate accounts for >90% of absorbed drug via glomerular filtration and tubular secretion; <1% excreted as parent oseltamivir in urine; fecal elimination <5%.
Category A/B
Category C
Neuraminidase Inhibitor
Neuraminidase Inhibitor